BioSpace News Archive

Ophthalmology is a branch of medicine related to the structure, functions, and diseases of the eye.

Percutaneous Coronary Intervention is a non-surgical procedure for the implantation of stent using a catheter to treat obstructive coronary artery disease and open up blocked or narrowed blood vessels.

The nerve biologic products market report is an-depth study of various trends, growth factors, and economic forecast.

The global Recombinant Human Endostatin market report is an-depth study of drivers, trends, and economic forecast.

Axonics Modulation Technologies, Inc., a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the virtual Barclays Global Healthcare Conference on March 10, 2021.

Eli Lilly and Company and Incyte announced top-line results from BRAVE-AA2, a Phase 3 study evaluating the efficacy and safety of once-daily baricitinib 2-mg and 4-mg in adults with severe alopecia areata.

Asensus Surgical , Inc. (formerly TransEnterix, Inc.) (NYSE American: TRXC) , a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, today announced the Company has received an additional FDA clearance for the Senhance Surgical System

Profound Medical Corp., a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced the appointment of Cynthia Lavoie Ph.D., MBA, to its Board of Directors.

- On track to initiate three Phase 1/2 clinical programs in the first half of 2021: PBGM01 for GM1 gangliosidosis (GM1), PBFT02 for frontotemporal dementia with granulin mutations, and PBKR03 for Krabbe disease - - Opened first U.S. site for PBGM01’s Imagine-1 global clinical program and actively recruiting patients; other site activations in progress - - Opening new CMC research and development site to support analytics, assay development, and product testing in 2Q 2021 - -

Company reports fourth quarter and full year 2020 XHANCE net revenue of $15.6 million and $48.4 million Full year 2020 XHANCE prescriptions increased 70% compared to full year 2019 Company expects XHANCE net revenue for 2021 to be at least $80 million